iBio, Inc. (IBIO) intrinsic value & 10-year financials
iBio, Inc. (IBIO) has a Graham intrinsic value of $14.77 per share. At $0.77 on Oct 17, 2026, the stock trades 95% below that value. Over the last 10 fiscal years revenue shrank 9.1% a year to $400.0K, with an average return on invested capital of -23.8%.
- Graham intrinsic value
- $14.77
- Share price (Oct 17, 2026)
- $0.77
- Price vs Graham value
- 95% below
- Market cap
- $8.0M
- Revenue (FY2025)
- $400.0K
- Revenue growth (10-yr CAGR)
- -9.1%
- ROIC (10-yr avg)
- -23.8%
- Free cash flow (FY2025)
- -$15.3M
IBIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $400.0K | -$18.4M | -$1.75 | -$15.3M | -4650.5% | -202.7% |
| FY2024 | $225.0K | -$24.9M | -$6.50 | -$18.8M | -7392.9% | -136.3% |
| FY2023 | $0 | -$65.0M | -$5.31 | -$36.2M | — | -96.4% |
| FY2022 | $2.4M | -$50.3M | -$5.78 | -$44.8M | -2085.2% | -91.0% |
| FY2021 | $2.4M | -$23.2M | -$3.00 | -$35.0M | -1312.1% | -64.5% |
| FY2020 | $0 | -$16.4M | — | -$14.4M | — | -88.8% |
| FY2019 | $37.0K | -$17.6M | — | -$14.9M | -42670.3% | 806.3% |
| FY2018 | $44.0K | -$16.1M | — | -$14.4M | -32334.1% | -113.5% |
| FY2017 | $394.0K | -$14.5M | — | -$14.5M | -3622.8% | -151.4% |
| FY2016 | $948.0K | -$9.8M | — | -$8.1M | -1043.6% | -99.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
iBio, Inc. is facing top-line stagnation, with revenue contracting over the decade.
iBio, Inc. has historically struggled to out-earn its cost of capital, averaging just -68.5% ROIC.
iBio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, iBio, Inc. is modeled at -9.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $14.77 per share.